News

Filter

Current filters:

ManagementOncology

1 to 9 of 18 results

Affymax decides to wind up company following demise of Omontys

Affymax decides to wind up company following demise of Omontys

25-06-2014

USA-based biotech firm Affymax says that its board of directors has approved the liquidation and dissolution…

AffymaxBiotechnologyFinancialManagementOmontysOncologyTakeda Pharmaceutical

SillaJen changes its name to mark Jennerex acquisition

20-06-2014

South Korean privately held pharma company SillaJen has changed its name to SillaJen Biotherapeutics…

Asia-PacificJennerexManagementMergers & AcquisitionsOncologyPexa-VecPharmaceuticalSillaJen

Novartis outlines aims to be more profitable and increasingly focused

Novartis outlines aims to be more profitable and increasingly focused

19-06-2014

Swiss drug major Novartis has set out its new focused portfolio at the first Meet Novartis Management…

EuropeManagementNovartisOncologyOphthalmicsPharmaceutical

Novartis nabs Merck's Bruno Strigini as president of oncology business

Novartis nabs Merck's Bruno Strigini as president of oncology business

01-06-2014

Swiss pharma major Novartis has announced the appointment of Bruno Strigini as president of Novartis…

BoardroomManagementOncologyPharmaceutical

Bristol-Myers Squibb refocuses R&D strategy

Bristol-Myers Squibb refocuses R&D strategy

08-11-2013

US drug major Bristol-Myers Squibb says it is “evolving its strategic focus in R&D to ensure continued…

Anti-viralsBristol-Myers SquibbDiabetesManagementNeurologicalOncologyPharmaceuticalResearch

AVEO Oncology restructuring and job cuts as tivozanib future in RCC in doubt

05-06-2013

Following a recent negative opinion on its lead product candidate from a Food and Drug Administration…

Astellas PharmaAVEO OncologyBiotechnologyFinancialManagementOncologyResearchtivozanib

Affymax slashes workforce following Omontys problems; evaluating options

19-03-2013

US biopharma company Affymax (Nasdaq: AFFY) says that it will reduce its workforce as part of a plan…

AffymaxBiotechnologyFinancialManagementOmontysOncologyPharmaceutical

Roche granted EU approval for Perjeta; board appointments

06-03-2013

The European Medicines Agency has approved Swiss drug major Roche's (ROG: SIX) Perjeta (pertuzumab) for…

BiotechnologyEuropeManagementOncologyPerjetaPharmaceuticalRegulationRoche

1 to 9 of 18 results

COMPANY SPOTLIGHT

Menarini

Back to top